Evidence map›Paper›PMID 16245163›Full record

ArticleTransgenic research2005

Development of transgenic mice expressing calcitonin as a beta-lactoglobulin fusion protein in mammary gland.

Ahmadreza Niavarani, Somaye Dehghanizadeh, Sirous Zeinali, Mohsen Karimi, Marc Magliano, Minoo Rassoulzadegan

Abstract read
PubMed Publisher
In one paragraph

Article in Transgenic research, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Ahmadreza NiavaraniDepartment of Biotechnology, Pasteur Institute of Iran, Tehran, Iran.
Somaye Dehghanizadeh
Sirous Zeinali
Mohsen Karimi
Marc Magliano
Minoo Rassoulzadegan
Pasteur Institute of Iran · IRInserm · FRUniversité Côte d'Azur · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Expression of foreign proteins in mammalian milk is becoming a widespread strategy for high-level production of recombinant pharmaceuticals, especially those with the most complex post-translational modifications. A milk-specific ovine beta-lactoglobulin (oBLG) promoter was used to drive expression of recombinant calcitonin in mouse milk. A gene construct was generated, consisting of 10.7 kbp of the oBLG gene including its promoter and 3' flanking region with the calcitonin coding sequences inserted in-frame into the oBLG fifth exon. After microinjection, six founder mice transmitted the transgene to their progeny. RT-PCR confirmed mammary-gland specific expression of recombinant mRNA in most transgenic mice and Western blot analysis confirmed expression of chimeric protein. Calcitonin can thus be expressed under the oBLG promoter and regulatory elements in a mammary-gland specific manner.

Indexed as

AnimalsBase SequenceCalcitoninDNA, RecombinantFemaleGene ExpressionLactoglobulinsMaleMammary Glands, AnimalMiceMice, Inbred DBAMice, TransgenicMilkPromoter Regions, GeneticRecombinant Fusion ProteinsSheepCalcitoninDNA, RecombinantLactoglobulinsRecombinant Fusion Proteins

Identifiers

PMID16245163
OpenAlexW2083436025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.